MA30475B1 - Acides biphenyl carboxyliques substitutes et derives en resultant. - Google Patents

Acides biphenyl carboxyliques substitutes et derives en resultant.

Info

Publication number
MA30475B1
MA30475B1 MA31395A MA31395A MA30475B1 MA 30475 B1 MA30475 B1 MA 30475B1 MA 31395 A MA31395 A MA 31395A MA 31395 A MA31395 A MA 31395A MA 30475 B1 MA30475 B1 MA 30475B1
Authority
MA
Morocco
Prior art keywords
derivatives
carboxylic acids
substituted biphenyl
biphenyl carboxylic
compounds
Prior art date
Application number
MA31395A
Other languages
English (en)
Inventor
Francis Wilson
Alison Reid
Valerie Reader
Richard John Harrison
Mihiro Sunose
Remedios Hernadez-Perni
Jeremy Major
Cyrille Boussard
Kathryn Smelt
Jess Taylor
Adeline Leformal
Andrew Cansfield
Svenja Burckhardt
Chih Yung Ho
Yan Zhang
Original Assignee
Ortho Mcneil Pharm Inc
Cellzome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc, Cellzome Ltd filed Critical Ortho Mcneil Pharm Inc
Publication of MA30475B1 publication Critical patent/MA30475B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La présente invention a pour objet des composés présentant la formule générale (I), les définitions de X, Y, R1,R.2, R3, R4 R9, et R10 données ci-dessous, et/ou un sel ou ester en dérivant. De plus la présente invention a pour objet l'emploi desdits composés pour le traitement de la maladie d'Alzheimer et leur emploi pour la modulation de l'activité de (gamma)-sécrétase.
MA31395A 2006-04-21 2008-11-20 Acides biphenyl carboxyliques substitutes et derives en resultant. MA30475B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112938A EP1849762B1 (fr) 2006-04-21 2006-04-21 Acides biphényl carboxyliques substitués et leurs dérivés

Publications (1)

Publication Number Publication Date
MA30475B1 true MA30475B1 (fr) 2009-06-01

Family

ID=36688012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31395A MA30475B1 (fr) 2006-04-21 2008-11-20 Acides biphenyl carboxyliques substitutes et derives en resultant.

Country Status (35)

Country Link
US (1) US7557244B2 (fr)
EP (2) EP1849762B1 (fr)
JP (1) JP5479088B2 (fr)
KR (1) KR101542255B1 (fr)
CN (1) CN101687758B (fr)
AP (1) AP2008004656A0 (fr)
AR (1) AR060568A1 (fr)
AU (1) AU2007240335B2 (fr)
BR (1) BRPI0710656A2 (fr)
CA (1) CA2650006C (fr)
CR (2) CR10375A (fr)
CY (1) CY1109399T1 (fr)
DE (1) DE602006007810D1 (fr)
DK (1) DK1849762T3 (fr)
EA (1) EA016129B9 (fr)
ES (2) ES2328616T3 (fr)
GE (1) GEP20115269B (fr)
GT (1) GT200900120A (fr)
IL (2) IL194852A0 (fr)
MA (1) MA30475B1 (fr)
MX (1) MX2008013445A (fr)
MY (1) MY148953A (fr)
NO (1) NO20084517L (fr)
NZ (1) NZ573000A (fr)
PE (1) PE20080364A1 (fr)
PL (1) PL1849762T3 (fr)
PT (1) PT1849762E (fr)
SI (1) SI1849762T1 (fr)
SM (1) SMP200800061B (fr)
TN (1) TNSN08413A1 (fr)
TW (1) TWI399362B (fr)
UA (1) UA95952C2 (fr)
UY (1) UY30301A1 (fr)
WO (1) WO2007124394A1 (fr)
ZA (1) ZA200809856B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818773A2 (pt) 2007-10-19 2015-04-14 Janssen Pharmaceutica Nv Moduladores de gama-secretase ligados a carbono
WO2009052350A1 (fr) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Modulateurs de la g-secrétase liés à une amine
ATE543799T1 (de) 2007-10-19 2012-02-15 Janssen Pharmaceutica Nv Piperidinyl- und piperazinylmodulatoren von g- sekretase
MX2010004311A (es) * 2007-10-19 2010-05-03 Janssen Pharmaceutica Nv Productos intermedios de moduladores de gamma-secretasa.
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2011046774A1 (fr) * 2009-10-16 2011-04-21 Merck Sharp & Dohme Corp. Dérivés d'éther diarylique comme inhibiteurs de la gamma-sécrétase n'agissant pas sur la voie notch
US8785481B2 (en) 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
WO2012119035A1 (fr) * 2011-03-03 2012-09-07 Treventis Corporation Composés anti-amyloïdes et procédés
WO2015109109A1 (fr) 2014-01-15 2015-07-23 Forum Pharmaceuticals Inc. Morpholino-pyrimidines fusionnées et leurs procédés d'utilisation
US9802927B2 (en) 2015-06-10 2017-10-31 Denali Therapeutics, Inc. Oxadiazine compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JP3802581B2 (ja) * 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
AU2001257022B2 (en) 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
EP1546086A2 (fr) * 2002-06-27 2005-06-29 Fujisawa Pharmaceutical Co., Ltd. Derives d'aminoalcool
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
WO2005110963A1 (fr) * 2004-05-19 2005-11-24 Cellzome Ag Acides (biphenyl-3-yl)-carboxyliques et derives de ceux-ci ainsi que leur utilisation en therapie
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
WO2006022237A1 (fr) * 2004-08-24 2006-03-02 Kissei Pharmaceutical Co., Ltd. Médicament servant à prévenir ou à traiter la stéatose hépatique
JP5155171B2 (ja) * 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物

Also Published As

Publication number Publication date
TW200815320A (en) 2008-04-01
NO20084517L (no) 2009-01-13
CA2650006A1 (fr) 2007-11-01
EP2021314A1 (fr) 2009-02-11
CN101687758B (zh) 2014-05-14
GT200900120A (es) 2009-11-16
US7557244B2 (en) 2009-07-07
EA016129B1 (ru) 2012-02-28
ZA200809856B (en) 2009-06-24
EP2021314B1 (fr) 2013-01-23
GEP20115269B (en) 2011-08-25
KR101542255B1 (ko) 2015-08-06
MY148953A (en) 2013-06-14
AU2007240335A1 (en) 2007-11-01
US20070293567A1 (en) 2007-12-20
SI1849762T1 (sl) 2009-12-31
UY30301A1 (es) 2007-08-31
TWI399362B (zh) 2013-06-21
JP2009544573A (ja) 2009-12-17
IL194852A0 (en) 2009-08-03
ES2400530T3 (es) 2013-04-10
SMP200800061B (it) 2009-07-14
AR060568A1 (es) 2008-06-25
WO2007124394A1 (fr) 2007-11-01
CA2650006C (fr) 2016-08-23
IL194790A (en) 2012-12-31
AU2007240335B2 (en) 2013-05-02
KR20090024679A (ko) 2009-03-09
BRPI0710656A2 (pt) 2011-08-16
CY1109399T1 (el) 2014-07-02
IL194790A0 (en) 2009-08-03
PE20080364A1 (es) 2008-05-16
CN101687758A (zh) 2010-03-31
CR10375A (es) 2009-02-26
UA95952C2 (ru) 2011-09-26
EP1849762A1 (fr) 2007-10-31
EA016129B9 (ru) 2012-06-29
CR10451A (es) 2009-03-31
MX2008013445A (es) 2009-03-10
JP5479088B2 (ja) 2014-04-23
EA200802172A1 (ru) 2009-06-30
SMAP200800061A (it) 2008-11-19
PL1849762T3 (pl) 2009-12-31
PT1849762E (pt) 2009-09-16
DE602006007810D1 (de) 2009-08-27
ES2328616T3 (es) 2009-11-16
AP2008004656A0 (en) 2008-10-31
NZ573000A (en) 2011-11-25
EP1849762B1 (fr) 2009-07-15
TNSN08413A1 (en) 2010-04-14
DK1849762T3 (da) 2009-10-12

Similar Documents

Publication Publication Date Title
MA30475B1 (fr) Acides biphenyl carboxyliques substitutes et derives en resultant.
MA29514B1 (fr) Acides carboxylique (biphenyle) et leurs derives
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
MA27472A1 (fr) Acetyle 2-hydroxy-1, 3 diaminoalcanes
EA200800975A1 (ru) ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
MA30420B1 (fr) Derives de terphenyle pour le traitment de la maladie d'alzheimer
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
EP1817312A4 (fr) Inhibiteurs de l'aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d'alzheimer
MA29464B1 (fr) Methode de preparation d'acides 1,6-dihydro-6-oxo-4-pyrimidinecarboxyliques eventuellement 2-substitues
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique
TN2009000470A1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
ATE409693T1 (de) Verfahren zur herstellung von 2-(4- chlorbenzoylamino-3- 2(1h)-chinolinon-4-yl propionsäure
ATE357453T1 (de) Comt-inhibitoren
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
MA33917B1 (fr) Dérivés d'acide carboxylique ayant un cycle oxazolopyrimidine 2,5-substitue
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren
MXPA06013503A (es) Uso de compuestos de kaureno en la manufactura de medicamentos.